瘤坏死因子抑制剂治疗增加了绝对淋巴细胞计数,并与患有牛皮病关节炎的患者的较低死亡率有关
Lenche Kostadinova1,2, Brigid Wilson1,2, Hinnah Siddiqui1
1Northeast Ohio Veterans Affairs Medical Center, Cleveland.
ACR open rheumatology
|December 16, 2025
概括
瘤坏死因子抑制剂 (TNFi) 治疗增加了牛皮关节炎 (PsA) 患者的绝对淋巴细胞计数 (ALC),从而改善了生存率. 这一发现表明TNFi影响T细胞平衡,并可能降低PsA的死亡率.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 临床医学 临床医学
背景情况:
- 牛皮关节炎 (PsA) 涉及瘤亡因子 (TNF) 信号传递.
- 较低的绝对淋巴细胞计数 (ALC) 与类风湿性关节炎的较高死亡率相关.
- TNF抑制剂 (TNFi) 治疗与ALC增加有关.
研究的目的:
- 为了研究TNFi对PsA患者ALC的影响.
- 为了确定ALC与接受TNFi治疗的PsA患者的死亡率之间的关联.
主要方法:
- 1923名PsA患者开始TNFi的回顾性队列研究 (2010-2015).
- 在TNFi启动 (3-24个月) 之前和之后的实验室测试分析.
- 匹配的对照和炎症标志物和ALC相关的评估.
主要成果:
- 在PSA患者中,TNFi启动增加了0.22 × 10^3/μL的平均ALC,而对照组的变化很小.
- 较高的基线和随访ALC与改善的生存率有关.
- 在TNFi治疗的PsA患者中较低的IL-6水平与ALC负相关.
结论:
- 在PSA患者中,TNFi治疗显著增加了外周血液ALC.
- 在TNFi之后增加的ALC与随后的死亡率降低有关.
- 潜在的机制包括TNFi,PsA和IL-6对T细胞子集恒温的影响.
更多相关视频
相关概念视频
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K


